# Cannabis Quality Control, Yeast & Mold Contaminants & Patient Safety > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/videos/cannabis-safety-mold-contaminants/ > **Published:** 2026-10-08T19:35:34-04:00 | **Last Modified / Clinically Audited:** 2026-10-20T19:25:23-04:00 > **Clinical Summary:** NBC Boston investigation with Dr. Benjamin Caplan examining cannabis testing regulations, yeast and mold contaminants, and essential patient safety standards. --- [Home](https://cedclinic.com/) / [Video Archive & Media Hub](https://cedclinic.com/videos/) / Quality Control & [Patient Safety](https://cedclinic.com/cbd-gummies-pain-management/) πŸ”¬ Public Health Alert & Clinical Toxicology Table of Contents - [Cannabis Quality Control, Yeast & Mold Contaminants, and Patient Safety](#Cannabis_Quality_Control_Yeast_038_Mold_Contaminants_and_Patient_Safety)[NBC Boston: State Warns Cannabis Consumers of Products Tainted With Yeast & Mold](#NBC_Boston_State_Warns_Cannabis_Consumers_of_Products_Tainted_With_Yeast_038_Mold) - [Massachusetts 60-Day Rolling Supply Limit & Dispensary Standards](#Massachusetts_60-Day_Rolling_Supply_Limit_038_Dispensary_Standards) - [The 4 Cornerstones of Safe Cannabinoid Therapy](#The_4_Cornerstones_of_Safe_Cannabinoid_Therapy)[🫁 Pulmonary Risks vs. Ingestion Safety](#_Pulmonary_Risks_vs_Ingestion_Safety) - [πŸ”¬ Reading Certificates of Analysis (COAs)](#_Reading_Certificates_of_Analysis_COAs) - [πŸ›‘οΈ High-Risk Populations Require Extra Care](#_High-Risk_Populations_Require_Extra_Care) - [πŸ§ͺ Remediation: Heat & Radiation Caveats](#_Remediation_Heat_038_Radiation_Caveats) - [Mass Medical Marijuana Online Registration: Protect Your Health & Rights](#Mass_Medical_Marijuana_Online_Registration_Protect_Your_Health_038_Rights) - [Explore Clinical & Media Investigations](#Explore_Clinical_038_Media_Investigations)[πŸŽ“ Doctor-to-Doctor Grand Rounds](#_Doctor-to-Doctor_Grand_Rounds) - [πŸŽ—οΈ Cancer Survivorship & Oncology](#_Cancer_Survivorship_038_Oncology) - [πŸ›οΈ Federal Policy & DEA Rescheduling](#_Federal_Policy_038_DEA_Rescheduling) - [🌍 Voice of America Documentary](#_Voice_of_America_Documentary) - [Need Help Selecting Safe, Lab-Verified Formulations?](#Need_Help_Selecting_Safe_Lab-Verified_Formulations) # Cannabis Quality Control, Yeast & Mold Contaminants, and Patient Safety NBC Boston investigative special with Dr. Benjamin Caplan: analyzing state dispensary recalls, the pulmonary dangers of fungal spores and mycotoxins in immunocompromised patients, and how to verify third-party Certificates of Analysis (COAs). 🚨 NBC Boston Statewide Recall Investigation 🫁 Pulmonary Aspergillosis Defense πŸ“‹ Third-Party COA Literacy ● Featured NBC Boston Investigation NBC 10 Boston β€’ Health & Consumer Watch [β–Ά Watch NBC Boston Investigation (Official Broadcast) β†—](https://www.nbcboston.com/news/local/mass-warns-marijuana-users-of-products-tainted-with-yeast-mold/3622745/) ### NBC Boston: State Warns Cannabis Consumers of Products Tainted With Yeast & Mold Following state health alerts and dispensary product recalls across Massachusetts, NBC Boston investigates how elevated total yeast and mold counts (TYMC) penetrate commercial supply chains. Dr. Benjamin Caplan delivers urgent clinical guidance for medical cannabis patients: while a healthy gastrointestinal tract can digest many spores harmlessly, inhaling burning or vaporized fungal pathogens like *Aspergillus* directly into pulmonary bronchioles can trigger severe pneumonia, bronchospasm, and potentially fatal invasive fungal infections in cancer patients, transplant recipients, and elderly individuals. [Watch Full NBC Broadcast β†—](https://www.nbcboston.com/news/local/mass-warns-marijuana-users-of-products-tainted-with-yeast-mold/3622745/) [Schedule Clinical Safety Review β†—](https://cedclinic.com/contact-ced-staff/) 🌿 State Law Patient Legal Rights & Quality Assurance ### Massachusetts 60-Day Rolling Supply Limit & Dispensary Standards Medical dispensaries in Massachusetts are held to significantly higher testing standards and microbial auditing than unregulated illicit channels. Certified medical patients are legally permitted to possess up to a 60-day rolling supply (up to 10 ounces of lab-verified cannabis). Read Dr. Caplan’s clinical breakdown of certified patient rights, sales-tax exemptions, and regulatory protections. [Read Massachusetts 60-Day Supply Guide β†—](https://cedclinic.com/massachusetts-60-day-rolling-supply-limit-medical-cannabis-2026/) Clinical Toxicology ## The 4 Cornerstones of Safe Cannabinoid Therapy How Dr. Caplan evaluates product safety to protect vulnerable patients from hazardous cultivation contaminants. Microbial Defense #### 🫁 Pulmonary Risks vs. Ingestion Safety When mold spores are ingested orally, hydrochloric acid in the stomach destroys the vast majority of fungal pathogens. In sharp contrast, inhaling mold through smoking or vaporizing deposits spores directly into alveoli, posing acute risk of allergic bronchopulmonary aspergillosis. Lab Literacy #### πŸ”¬ Reading Certificates of Analysis (COAs) Every state-licensed batch must generate a third-party Certificate of Analysis. Patients must check that total yeast and mold counts (TYMC) fall safely below regulatory limits (typically --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).